QPS — research payments reported | Open Payments Record

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$900,148	7
2024	Research	$328,617	9
2023	Research	$716,749	11
2022	Research	$113,670	4
2021	Research	$292,335	13
2020	Research	$739,255	16

Breakdown

Who paid Research payments · program years 2020–2025

E.R. Squibb & Sons, L.L.C. $1,246,338 22 payments
Bayer HealthCare Pharmaceuticals Inc. $1,031,590 29 payments
Vanda Pharmaceuticals Inc. $630,391 4 payments
Celgene Corporation $182,455 5 payments

Studies the money was for Research payments · program years 2020–2025

BAY1753011 Age and Gender $814,461 21 payments
An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioavailability of 5 ML Tradipitant Liquid Suspension Formulation Relative to 85 MG Tradipitant Capsule Formulation in Healthy Volunteers $615,372 3 payments
SAD/MAD/FE/FB - A Phase 1, Randomized, Multi-Part, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986421 in Healthy Participants $310,982 1 payment
BAY2433334 age and gender $217,129 8 payments
PK Bridging (PFS vs Autoinjector) $169,840 3 payments
Relative BA / Pilot FE (NHV) - A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and Relative Bioavailability of BMS-986365 Capsule Com $164,678 1 payment
A Phase 1, Open-label, Two-Part Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants $151,498 2 payments
DDI study with CYP3A4 and P-gp inhibitors in Healthy Volunteers $115,339 2 payments
Clin Pharm SAD/FE Study - A Phase 1, Two-part Study to Evaluate the Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of BMS-986369 and to Explore the Effect of Food the Bioavailability of BMS-986369 in Healthy Participants $108,781 2 payments
DDI (OC dose 2 -3 weeks) - A Phase 1, Single-center, Open-label, Single-sequence Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 With Oral Contraceptives in Healthy Female Participants $95,578 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.